title: Impact of immediate breast reconstruction on postoperative adjuvant chemotherapy: a single center study.
abstract: BACKGROUND
  Various studies have indicated a worldwide increase in the number of immediate breast reconstruction surgeries. However, breast reconstruction should not delay or prevent postoperative cancer therapeutics such as adjuvant chemotherapy and radiotherapy. In response to these developments, our team researched the impact of immediate breast reconstruction on postoperative adjuvant chemotherapy.
  
  
  METHODS
  From April 2006 to March 2011, 116 patients at Saitama Cancer Center underwent postoperative adjuvant chemotherapy following mastectomy with or without immediate breast reconstruction. Fifty patients received postoperative adjuvant chemotherapy following mastectomy with immediate breast reconstruction (IBR group), and 66 patients received the same treatment but without immediate breast reconstruction (non-IBR group). The outcomes were studied retrospectively by chart review. Patients' average age, body mass index, postoperative complication rate, and days to adjuvant chemotherapy were calculated.
  
  
  RESULTS
  Mean age and body mass index of patients were 47.0 ± 9.0 years, 22.2 ± 3.0 kg/m(2) and 55.5 ± 10.1 years, 23.0 ± 3.6 kg/m(2) in IBR group and non-IBR group, respectively. Postoperative complication rate was 10.0 % in IBR group and 6.1 % in non-IBR group. Days to adjuvant chemotherapy was 61.0 ± 10.5 days in IBR group and 58.0 ± 12.3 days in non-IBR group.
  
  
  CONCLUSIONS
  Although complication rate and days to adjuvant chemotherapy were slightly increased in IBR group, the delay was not critical to the initiation of adjuvant chemotherapy in these patient groups.
authors.affiliation: Division of Plastic and Reconstructive Surgery, Saitama Cancer Center, 818 Komuro, Inamachi, Kitaadachigunn, Saitama, Japan, a.hamahata@gmail.com.
authors.forename: Atsumori
authors.initials: A
authors.lastname: Hamahata
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Kubo
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Takei
authors.forename: Takashi
authors.initials: T
authors.lastname: Saitou
authors.forename: Yuji
authors.initials: Y
authors.lastname: Hayashi
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Matsumoto
authors.forename: Shigenori
authors.initials: S
authors.lastname: Nagai
authors.forename: Kenichi
authors.initials: K
authors.lastname: Inoue
authors.forename: Masafumi
authors.initials: M
authors.lastname: Kurosumi
authors.forename: Takashi
authors.initials: T
authors.lastname: Yamaki
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Sakurai
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016462:Mammaplasty; D008875:Middle Aged; D009367:Neoplasm Staging; D011183:Postoperative Complications; D011379:Prognosis; D012189:Retrospective Studies; D013997:Time Factors